BioticsAI on Clearing the FDA, Raising Money and Keeping a Team Motivated in Healthtech

BioticsAI CEO Robhy Bustami appeared on the Build Mode podcast with a candid account of what it is really like to build an AI company in healthcare, from getting through the FDA to talking with investors and keeping the team together.

Why healthcare is a special case

Most tech startups work on a "launch and see" principle: ship a feature, measure the reaction, adjust. In healthcare, that logic breaks down. Every change to an algorithm that affects clinical decisions can potentially require fresh FDA approval.

Bustami described how BioticsAI built its processes around regulatory requirements from the start. This is not just bureaucracy. It is a different development philosophy: you think about validation and documentation first, and release speed second. Companies that try to "add compliance later" inevitably rewrite their architecture and lose months at a stage when the cost of a mistake is especially high.

The FDA: how not to get stuck in bureaucracy

One of the key insights is a rethinking of the regulator's role. Many startups see the FDA as an obstacle. Bustami proposes a different frame: the regulator sets a quality standard that protects both patients and the company's reputation.

In practice, this means engaging with the FDA early, before any official submission. Preliminary consultations help you understand the regulator's expectations and avoid spending months on a package that comes back with comments.

A typical approval path in healthtech AI includes:

• Determining the product class (Class I, II or III)
• Preparing a technical file with clinical data
• A preliminary consultation with the FDA (Pre-Sub meeting)
• Formal submission via the 510(k) or De Novo pathway
• A review period ranging from several months to a year
• Post-market monitoring after approval

Fundraising with a regulatory tail

Raising money in healthtech is a discipline of its own. Venture investors used to SaaS expect product-market fit within 18-24 months. In healthcare, that logic does not hold: the regulatory path stretches timelines, and investment milestones look different.

Bustami said the BioticsAI team learned to present regulatory progress as an investment narrative. FDA Breakthrough Device Designation, first clinical partnerships and publications in peer-reviewed journals all become markers of maturity that specialized healthtech investors value.

Motivating a team in a slow-moving world

In tech startups, the usual fuel is frequent wins: a new feature every two weeks, metric growth every month. In healthcare, development runs for months without visible results for users. That requires a different culture.

At BioticsAI, they learned to celebrate intermediate milestones: the first talks with the FDA, the first clinical partner, the first successful test. This replaces the usual dopamine signals and keeps the team focused on the mission rather than on short-term metrics.

What this means

Healthcare AI is not just the next market for LLMs. It is an industry where the cost of a regulatory error is measured in lives and billion-dollar lawsuits. Startups that build compliance into their culture from day one gain a long-term competitive advantage, and improve their odds of making the whole journey from prototype to clinical use.